Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Zervas

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Thalidomide and dexamethasone combination for refractory multiple myelomaM A Dimopoulos, K Zervas, G Kouvatseas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemiaM A Dimopoulos, G Hamilos, K Zervas, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaM A Dimopoulos, A Pouli, K Zervas, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Thalidomide and dexamethasone combination for refractory multiple myelomaM A Dimopoulos, K Zervas, G Kouvatseas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemiaM A Dimopoulos, G Hamilos, K Zervas, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaM A Dimopoulos, A Pouli, K Zervas, et al.
Pageof 2